Cite
HARVARD Citation
Sydes, M. et al. (2018). Adding abiraterone or docetaxel to long-term hormone therapy for prostate cancer: directly randomised data from the STAMPEDE multi-arm, multi-stage platform protocol. Annals of oncology. pp. 1235-1248. [Online].